Jump to content

Ascrinvacumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 03:35, 21 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ascrinvacumab
Monoclonal antibody
Type?
SourceHuman
Targetactivin receptor-like kinase 1
Clinical data
Other namesPF-03446962
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6396H9850N1694O2012S44
Molar mass144079.64 g·mol−1

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by Pfizer Inc.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ascrinvacumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ascrinvacumab&oldid=963671208"